Keros Therapeutics Presented Additional Data From Its Ongoing Phase 2 Trial Of KER-050 In Patients With Very Low-, Low-, Or Intermediate-Risk Myelodysplastic Syndromes, And Preclinical Data Showing KER-050 To Restore Erythropoiesis In Myelofibrosis
Portfolio Pulse from Benzinga Newsdesk
Keros Therapeutics presented additional data from its ongoing Phase 2 trial of KER-050 in patients with myelodysplastic syndromes and preclinical data showing KER-050 to restore erythropoiesis in myelofibrosis. The company also announced preclinical data evaluating ALK2 inhibition and its combination with KER-050 as potential treatment options for anemia of inflammation.
June 09, 2023 | 10:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Keros Therapeutics released additional data from its Phase 2 trial of KER-050, showing potential in treating myelodysplastic syndromes and anemia of inflammation.
The additional data from the ongoing Phase 2 trial of KER-050 and the preclinical data evaluating ALK2 inhibition show potential in treating myelodysplastic syndromes and anemia of inflammation. This positive news may lead to increased investor interest and a potential short-term increase in Keros Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100